Core Insights - Elevance Health reported fourth quarter and full year 2025 results, showing disciplined execution in a dynamic environment and a focus on advancing affordability and healthcare accessibility for members [2][4]. Financial Performance - Operating revenue for Q4 2025 was $49.3 billion, a 10% increase from Q4 2024, while total operating revenue for 2025 reached $197.6 billion, up 13% year-over-year [4][11]. - The operating gain for Q4 2025 was $0.3 billion, with an adjusted operating gain of $0.4 billion, reflecting a decrease compared to the previous year [4][12]. - The benefit expense ratio increased to 93.5% in Q4 2025, up 110 basis points from the prior year, driven by higher medical costs [5][25]. Segment Performance - The Health Benefits segment generated $41.8 billion in operating revenue for Q4 2025, an 11% increase compared to Q4 2024, with a full year revenue of $167.1 billion, also up 11% [10][11]. - Carelon segment reported operating revenue of $18.7 billion in Q4 2025, a significant increase of 27% year-over-year, driven by growth in CarelonRx and Carelon Services [15][29]. Membership Metrics - Medical membership totaled approximately 45.2 million as of December 31, 2025, a decrease of 0.5 million or 1% year-over-year, primarily due to attrition in the Medicaid business [13][22]. Cash Flow and Shareholder Returns - Operating cash flow for 2025 was $4.3 billion, approximately 0.8 times GAAP net income, with cash and investments at the parent company totaling $2.6 billion as of December 31, 2025 [8][26]. - The company repurchased 1.4 million shares for $471 million in Q4 2025 and declared a quarterly dividend of $1.71 per share, totaling $377 million in cash distribution [9][17].

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Elevance became the second major insurer to predict declining revenue in 2026 on Wednesday, as for-profit payers continue to shave off members to try and recover margins. The Indianapolis-based insurer estimated its operating revenue will drop by a low-single digit percentage next year. The guidance comes one day after UnitedHealth forecast an ...

The Nasdaq led US stock futures higher on Wednesday as AI trade fervor spread ahead of the Federal Reserve’s latest policy decision and earnings from megacap techs. Contracts on the tech-heavy Nasdaq 100 (NQ=F) climbed about 0.9%, while those on the Dow Jones Industrial Average (YM=F) hovered below the flat line. S&P 500 futures (ES=F) moved up 0.3% on the heels of an all-time closing high. Techs are set to buoy markets again as a surprise record surge in orders for ASML's (ASML) chipmaking machines sto ...

Humana跌17%，Elevance Health跌8%，Centene跌超7%。 (本文来自第一财经) Humana跌17%，Elevance Health跌8%，Centene跌超7%。 (本文来自第一财经) ...

Core Viewpoint - The stock prices of major U.S. health insurance companies have experienced significant declines in pre-market trading on January 27, with Humana dropping 17%, Elevance Health falling 8%, Centene decreasing by 7.7%, and Molina Healthcare declining by 7.3% [1] Company Summary - Humana's stock price decreased by 17% in pre-market trading [1] - Elevance Health's stock price fell by 8% in pre-market trading [1] - Centene's stock price declined by 7.7% in pre-market trading [1] - Molina Healthcare's stock price dropped by 7.3% in pre-market trading [1] Industry Summary - The health insurance industry is facing a downturn, as evidenced by the significant stock price drops of major companies [1]

Group 1 - The U.S. government proposed an average increase of only 0.09% in Medicare payments to insurance companies for the next year, leading to a significant drop in stock prices for Medicare insurers [1] - The Centers for Medicare & Medicaid Services (CMS) indicated that the proposal would provide an additional payment of over $700 million for Medicare Advantage plans in 2027 [1] - Major insurance companies such as UnitedHealth, CVS, and Humana saw their stock prices decline by nearly 12% in after-hours trading, while Elevance Health and Molina Healthcare experienced a drop of nearly 5% [1]

Core Viewpoint - Elevance Health (ELV) is expected to report a quarterly earnings per share (EPS) of $3.07, reflecting a decline of 20.1% year-over-year, while revenues are forecasted to increase by 10.1% to $49.53 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower in the last 30 days, indicating a reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Revenue Projections - Analysts predict 'Revenues- Service fees' at $2.13 billion, a year-over-year increase of 4.7% [5]. - 'Revenues- Premiums' are estimated at $40.69 billion, reflecting a 12.3% year-over-year increase [5]. - 'Revenues- Net investment income' is expected to reach $469.69 million, indicating a decline of 10.9% year-over-year [5]. - 'Revenues- Product revenue' is projected at $6.82 billion, a 1.5% year-over-year increase [6]. Membership Metrics - Total Medical Membership is projected to be 45.40 million, down from 45.73 million in the same quarter last year [6]. - 'Medical Membership - Medicare - Medicare Advantage' is estimated at 2.24 million, up from 2.07 million year-over-year [7]. - 'Medical Membership - Medicaid' is expected to be 8.60 million, down from 8.92 million year-over-year [7]. - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.63 million, slightly down from 1.66 million year-over-year [8]. - Total Medicare membership is expected to reach 3.11 million, up from 2.96 million year-over-year [8]. - 'Medical Membership - Commercial Risk-Based - Individual' is estimated at 1.33 million, up from 1.29 million year-over-year [9]. - 'Benefit Expense Ratio' is forecasted to be 93.4%, compared to 92.4% year-over-year [9]. - 'Medical Membership - Commercial Fee-Based' is expected to be 27.08 million, down from 27.20 million year-over-year [9]. Stock Performance - Elevance Health shares have returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [10]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market [10].

Core Viewpoint - Elevance Health, Inc. (ELV) is expected to report its fourth-quarter 2025 results on January 28, 2026, with earnings estimated at $3.10 per share and revenues of $49.59 billion [1] Financial Performance - The fourth-quarter earnings estimate has seen one downward revision and no upward revisions in the past month, indicating a year-over-year decline of 19.3% in earnings, while revenues are projected to increase by 10.2% year-over-year [2] - For the full year 2025, the Zacks Consensus Estimate for Elevance's revenues is $197.98 billion, reflecting a 13% year-over-year increase, while the EPS estimate is $29.99, showing a 9.2% year-over-year decrease [3] Earnings Prediction - The current Earnings ESP for Elevance is -1.41%, and it holds a Zacks Rank of 4 (Sell), suggesting that an earnings beat is unlikely this quarter [4] Revenue Drivers - The consensus estimate for product revenues indicates a 1.5% growth from the previous year's $6.7 billion, while premiums are expected to rise by 12.3% year-over-year, contributing to overall sales growth [5] - The estimate for Commercial Individual membership suggests a 3.5% growth year-over-year, although Commercial Fee-based memberships are projected to decline by 0.4% [6] Operating Income - The Zacks Consensus Estimate for Carelon brand's operating income indicates an 8.9% year-over-year increase, driven primarily by growth in CarelonRx, while the Health Benefits segment's operating income is expected to rise by 12.1% [7] Expense Outlook - Elevated expenses are anticipated due to significant investments in digital capabilities, with total expenses expected to increase by 8.4% year-over-year in the fourth quarter [8]

Group 1 - The company Elevra Lithium Limited will release its December 2025 Quarterly Activities Report on January 28, 2026 AEDT [1] - An investor webcast will be held on the same day at 10.30am AEDT to discuss the quarterly results [1] - Retail shareholders and investors can participate in the webcast and submit written questions [2] Group 2 - Elevra has changed its presentation currency from Australian dollars to United States dollars effective July 1, 2025 [4] - This change aims to align with the predominant currency of revenue generation, providing clearer performance insights by reducing foreign exchange volatility [5] - The December 2025 Quarterly Report and FY26 Half-Year financial results will be presented in USD, with historical information also included for comparison [6]

Core Insights - Elevance Health Inc. (NYSE:ELV) is identified as a potentially undervalued stock within the S&P 500, with recent price target increases from analysts indicating positive sentiment towards the company [1][2]. Analyst Ratings and Price Targets - Mizuho analyst Ann Hynes raised the price target for Elevance Health to $413 from $400, maintaining an Outperform rating, while also noting a slowdown in healthcare utilization growth, suggesting a peak in recent healthcare demand [1][3]. - Wells Fargo increased its price target for Elevance Health to $424 from $403, maintaining an Overweight rating, with a focus on confidence in Medicare Advantage amidst uncertainties in Medicaid and health insurance exchanges [2]. Market Environment and Future Outlook - Mizuho anticipates a challenging environment for hospitals in 2026 as post-COVID tailwinds fade and legislative risks emerge, indicating potential headwinds for the healthcare sector [3]. - The ongoing debate regarding healthcare distributors revolves around whether performance will be influenced more by earnings revisions or valuation multiples, highlighting the complexities in the market [3]. Company Overview - Elevance Health operates as a health benefits company in the US, with four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, indicating a diversified business model [4].